Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Inclusive Healthcare for Transgender Individuals: Insights From a Healthcare Professional’s Transition Experience

In this podcast, Olivia Buckoski, PharmD, shares her personal experience undergoing medical and social transition, along with actionable advice for healthcare professionals caring for transgender individuals.
Olivia Buckoski, PharmD
Released: May 2, 2022

In this episode, Pharmacist Olivia Buckoski shares her experience undergoing medical and social transition and offers advice from the perspective of both a transgender person and healthcare professional on caring for transgender individuals. Topics include:

  • Importance of educating entire care team about needs of transgender individuals, starting with the waiting room
  • Specific advice for the exam room
  • Pharmacy and adherence considerations with hormone therapy
  • Examples of uninformed care

Information on this Educational Activity

Faculty

Olivia Buckoski, PharmD

Patient

Olivia Buckoski, PharmD, has no relevant conflicts of interest to disclose.

Program Medium

This program has been made available online.

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Educational grant provided by:
Merck Sharp & Dohme Corp.

Related Content

AMBER trial of cobolimab and dostarlimab shows manageable safety in advanced solid tumors and promising activity in advanced melanoma, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 20, 2022

CheckMate 067 7.5-year follow-up with nivolumab + ipilimumab in advanced melanoma, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 16, 2022

Data from the TRICOTEL study of the combination of atezolizumab, cobimetinib, and vemurafenib in advanced BRAFV600-mutated melanoma with CNS metastases, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 15, 2022

First-line therapy with camrelizumab, apatinib, and temozolomide for advanced acral melanoma showed promising antitumor activity and manageable toxicity, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 13, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings